Stratospheric Data Analysis System (STRATAN)

A state of the art stratospheric analyses using a coupled stratosphere/troposphere data assimilation system is produced. These analyses can be applied to stratospheric studies of all types. Of importance to this effort is the application of the Stratospheric Data Analysis System (STRATAN) to constituent transport and chemistry problems

Office Note Series on Global Modeling and Data Assimilation

The Data Assimilation Office (DAO) at Goddard Space Flight Center is currently producing a multiyear gridded global atmospheric dataset using a fixed assimilation system designed to remove the variability due to algorithm changes. While the signal due to system changes has been eliminated, changes in the input data are another potential source of spurious climate signals. In this study, a set of sensitivity experiments are performed with the Goddard Earth Observing System Version 1 (GEOS-1) assimilation system to assess the impact of including temperature and moisture information from stations on the NCEP's (National Centers for Environmental Prediction) reject list. The results from the sensitivity experiments for the northern summer of 1994 indicate that the impact of including the reject list reports is significant in the tropics. The most significant difference is found in the precipitation over the Indian summer monsoon region and the western Pacific. The precipitation without the..

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit